SUMEDHA PHARMA LIMITED

Company Registration Number:
11781923 (England and Wales)

Unaudited abridged accounts for the year ended 31 January 2026

Period of accounts

Start date: 01 February 2025

End date: 31 January 2026

SUMEDHA PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 31 January 2026

Balance sheet
Notes

SUMEDHA PHARMA LIMITED

Balance sheet

As at 31 January 2026


Notes
2026
2025


£
£
Called up share capital not paid: 0 0
Fixed assets
Intangible assets: 3 329,000 352,500
Tangible assets:   0 0
Total fixed assets: 329,000 352,500
Current assets
Stocks: 30,000 30,000
Debtors:   136,424 139,182
Cash at bank and in hand: 35,825 54,243
Total current assets: 202,249 223,425
Creditors: amounts falling due within one year:   (307,334) (334,270)
Net current assets (liabilities): (105,085) (110,845)
Total assets less current liabilities: 223,915 241,655
Creditors: amounts falling due after more than one year:   (336,623) (346,019)
Total net assets (liabilities): (112,708) (104,364)
Capital and reserves
Called up share capital: 100 100
Profit and loss account: (112,808) (104,464)
Shareholders funds: (112,708) (104,364)

The notes form part of these financial statements

SUMEDHA PHARMA LIMITED

Balance sheet statements

For the year ending 31 January 2026 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 31 October 2026
and signed on behalf of the board by:

Name: Neha Kansal
Status: Director

The notes form part of these financial statements

SUMEDHA PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2026

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Financial Reporting Standard 101

SUMEDHA PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2026

2. Employees

2026 2025
Average number of employees during the period 5 5

SUMEDHA PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 January 2026

3. Intangible Assets

Total
Cost £
At 01 February 2025 470,000
At 31 January 2026 470,000
Amortisation
At 01 February 2025 117,500
Charge for year 23,500
At 31 January 2026 141,000
Net book value
At 31 January 2026 329,000
At 31 January 2025 352,500